GN43271 – A biological drug to treat relapsing Multiple Sclerosis

GN43271 – A biological drug to treat relapsing Multiple Sclerosis

$

This study evaluates the safety and effectiveness of fenebrutinib in treating Relapsing Multiple Sclerosis.

$

This trial is not accepting new patients.

$

The purpose of this study is to compare the effects, good or bad, of fenebrutinib versus placebo in participants with RMS. The study has 4 parts: Screening, Blinded study treatment, optional open-label study treatment, and follow-up

$

Basic Enrollment Criteria:

  • Age 18-55 years old, Male & Female
  • Willing to comply with study visits and requirements
$

Study Length:

  • 3 months to 2 years

Participate In This Study

Sign-up Here